C/EBP-β-mediated upregulation of CaV1.2 calcium channel increases arterial constriction in mice with ibrutinib-associated hypertension
Ibrutinib, a Bruton's tyrosine kinase inhibitor, is indicated for treating chronic lymphocytic leukemia (CLL), but hypertension is a common cardiovascular adverse event. Previous studies have linked ibrutinib to cardiac events through dysregulated intracellular calcium handling, but the mechanisms underlying ibrutinib-associated hypertension remain largely unknown. Here, we followed up 225 CLL patients receiving ibrutinib or managed with watch-and-wait strategy, and identified ibrutinib as an independent risk factor for hypertension. In mice, ibrutinib elevated arterial blood pressure (BP) without structural remodeling of small arteries, and it potentiated K+-induced vasoconstriction. In vascular smooth muscle cells (VSMCs), ibrutinib upregulated CaV1.2 channel expression and function, as evidenced by enhanced CaV1.2 currents and K+-triggered-[Ca2+]i elevation. Mechanistically, ibrutinib suppressed casein kinase 2 (CK2)-mediated HSP90β phosphorylation, and stabilized C/EBP-β, which bound to the promoter of Cacna1c gene and drove CaV1.2 transcription. Significantly, C/EBP-β knockdown attenuated ibrutinib-induced CaV1.2 hyperactivity and vasoconstriction. Collectively, these findings reveal a CK2-HSP90β-C/EBP-β-CaV1.2 signaling cascade through which ibrutinib enhances vascular Ca2+ influx and vasoconstriction, thereby elevating arterial BP. Thus, this study nominates C/EBP-β as a therapeutic target for ibrutinib-associated hypertension.
Authors
- Juejin Wang (ORCID: https://orcid.org/0000-0003-4921-5451)
- 高晓燕
- Xiao‐Qing Xiong (ORCID: https://orcid.org/0000-0003-4143-5097)
- Ludan Zhang
- Yun Liu
- Wei Hou
- Xiaolin Sun
- Jianyong Li
- Yiyuan Jia
- Dan Yang
- Ming Chu
- Sirui Zhao
- Xiao Lu
- Huayuan Zhu
- Shumin Yin
- Yan Wang
Institutions
- Nantong University (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
- Jiangsu Province Hospital (CN)
- Taizhou University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Clinical Investigation
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1172/jci203386
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National University of Singapore
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Nanjing Medical University
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Qinglan Project of Jiangsu Province of China